参考文献/References:
[1] Skov J, Persson F, Frøkiræ J,et al. Tissue renin-angiotensin systems: a unifying hypothesis of metabolic disease[J].Front Endocrinol(Lausanne),2014,5:23.DOI: 10.3389/fendo.2014.00023.
[2] Kazafeos K. Incretin effect: GLP-1, GIP, DPP4[J].Diabetes Res Clin Pract,2011,93(Suppl 1):S32-S36. DOI: 10.1016/S0168-8227(11)70011-0.
[3] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP[J]. Gastroenterology,2007,132(6):2131-2157.
[4] Pyke C, Heller RS, Kirk RK,et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J].Endocrinology,2014,155(4):1280-1290.DOI: 10.1210/en.2013-1934.
[5] Fujita H, Morii T, Fujishima H,et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential[J]. Kidney Int,2014,85(3):579-589.DOI: 10.1038/ki.2013.427.
[6] Skov J, Dejgaard A, Frkiøræ J,et al. Glucagon-like peptide-1(GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men[J].J Clin Endocrinol Metab,2013,98(4):E664-E671. DOI: 10.1210/jc.2012-3855.
[7] Ishibashi Y, Matsui T, Ojima A,et al. Glucagon-like peptide-1 inhibits angiotensin Ⅱ-induced mesangial cell damage via protein kinase A[J].Microvasc Res,2012,84(3):395-398. DOI: 10.1016/j.mvr.2012.06.008.
[8] Mima A, Hiraoka-Yamomoto J, Li Q,et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes[J].Diabetes,2012,61(11):2967-2979. DOI: 10.2337/db11-1824.
[9] Hirata K, Kume S, Araki S,et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model[J].Biochem Biophys Res Commun,2009,380(1):44-49. DOI: 10.1016/j.bbrc.2009.01.003.
[10] 赵伟,陈光敏,孙蓓,等.利拉鲁肽对糖尿病大鼠肺组织局部RAS活性及TGF-β1,Ⅲ型胶原蛋白表达的影响[J].中华医学杂志,2014,94161:459-463.DOI:10.3760/cma.j.issn.0376-2491.2014.06.016.
[11] Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM,et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats[J].Endocrinology,2015,156(10):3559-3569.DOI:10.1210/en.2014-1685.
[12] Nagayama K, Kyotani Y, Zhao J, et al. Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin Ⅱ via the inhibition of ERK1/2 and JNK signaling pathways[J].PLoS One,2015,10(9):e0137960.DOI: 10.1371/journal.pone.0137960.
[13] Zhao L, Li AQ, Zhou TF, et al. Exendin-4 alleviates angiotensin Ⅱ-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway[J].Am J Physiol Cell Physiol,2014,307(12):C1130-C1141. DOI: 10.1152/ajpcell.00151.2014.
[14] Zhang LH, Pang XF, Bai F,et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin Ⅱ-induced tissue fibrosis by altering AT1/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart[J].Cardiovasc Drugs Ther,2015,29(3):243-255. DOI: 10.1007/s10557-015-6592-7.
[15] Rodriguez R, Viscarra JA, Minas JN,et al. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome[J].Endocrinology,2012,153(4):1684-1695. DOI: 10.1210/en.2011-1885.
[16] Shen M, Sun D, Li W,et al. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine]on vascular oxidative stress and inflammation in type 2 diabetic mice[J].Exp Diabetes Res,2012,2012:146194. DOI: 10.1155/2012/146194.
[17] Gnudi L, Karalliedde J. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents[J].Nephrol Dial Transplant,2016,31(7):1036-1043. DOI: 10.1093/ndt/gfv093.
[18] Fujiwara W, Izawa H, Ukai G,et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles[J].Heart Vessels,2013,28(3):316-322. DOI: 10.1007/s00380-012-0246-5.
[19] Miyagawa K, Kondo T, Goto R,et al. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes[J].Cardiovasc Diabetol,2013,12:160. DOI: 10.1186/1475-2840-12-160.
[20] Liang J, Leung KK, Lam SY,et al. Combined treatment with a dipeptidyl peptidase-IV inhibitor(sitagliptin)and an angiotensin Ⅱ type 1 receptor blocker(losartan)promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells[J]. Diabetes Obes Metab,2012,14(9):842-851. DOI: 10.1111/j.1463-1326.2012.01612.x.
[21] Cheng Q, Leung PS. An update on the islet renin-angiotensin system[J]. Peptides,2011,32(5):1087-1095. DOI: 10.1016/j.peptides.2011.03.003.
[22] Wang HW, Mizuta M, Saitoh Y,et al. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells[J].Metabolism,2011,60(8):1081-1089. DOI: 10.1016/j.metabol.2010.11.004.
[23] Artinian SB, Al Lafi SM, Boutary SS,et al. Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts[J].Exp Diabetes Res,2011,2011:489708. DOI: 10.1155/2011/489708.
[24] Fujita H, Taniai H, Murayama H,et al. DPP-4 inhibition with alogliptin on top of angiotensin Ⅱ type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy[J].Endocr J,2014,61(2):159-166.
[25] Alter ML, Ott IM, von Websky K,et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy[J].Kidney Blood Press Res,2012,36(1):119-130.DOI: 10.1159/000341487.
相似文献/References:
[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(05):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(05):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(05):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[6]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[7]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(05):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[8]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(05):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
[9]宋利革,李静,康志强.雌激素和新型冠状病毒肺炎的相关性[J].国际内分泌代谢杂志,2020,40(06):382.[doi:10.3760/cma.j.cn121383-20200306-03014]
Song Lige,Li Jing,Kang Zhiqiang.Correlation between estrogen and COVID-19[J].International Journal of Endocrinology and Metabolism,2020,40(05):382.[doi:10.3760/cma.j.cn121383-20200306-03014]
[10]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(05):645.[doi:10.3760/cma.j.cn121383-20200924-09046]